Categories for COVID-19/Coronavirus
Capricor Therapeutics, a clinical-stage biotechnology company focused on the development of the first-in-class cell and exosome-based therapeutics for the treatment and prevention of serious diseases, and Lonza today announced that the companies have entered into an agreement for the development of CAP-1002, Capricor's leading clinical asset using allogeneic cardiosphere-derived cells (CDC) technology for the treatment of Duchenne Muscular Dystrophy (DMD) and complications arising from COVID-19.
January 12, 2021
SOCMA member Lonza congratulates Moderna on interim Phase 3 clinical trial data.
November 16, 2020
Lonza announced today that the company has signed
an agreement with AstraZeneca to manufacture AZD7442, a combination of two long-acting antibodies (LAABs) for the potential prevention and treatment of COVID-19.
October 30, 2020
Humanigen, a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper response called ‘cytokine storm,’ and Lonza today announced a strategic collaboration to expand the manufacturing capacity for lenzilumab, currently in Phase 3 clinical trials for COVID-19, in advance of potential Emergency Use Authorization in 2020 and subsequent commercialization.
September 16, 2020
OSHA has issued two revised guidance memos on recordkeeping and enforcement in response to the COVID-19 pandemic. On May 26, 2020, the previous memos from April on these topics will be rescinded, and the new memos will go into and remain in effect until further notice.
May 20, 2020
Internationally respected demographer, Ken Gronbach, stated the U.S. economy would not suffer as a result of COVID-19 because of it's position in the global landscape.
May 14, 2020
In this post, SOCMA shares the following core considerations for developing return to work plans. The following information was compiled based on information shared during a SOCMA roundtable with DanChem, Strem Chemicals, Inc and Sun Chemical Corporation. A template return to work plan is in development and will be available in the coming week.
May 8, 2020
Moderna, Inc. and Lonza Ltd. today announced a 10-year strategic collaboration agreement to enable larger scale manufacture of Moderna's mRNA vaccine (mRNA-1273) against the novel coronavirus (SARS-CoV-2) and additional Moderna products in the future.
May 5, 2020
April 20, 2020 Re: FEMA Initiative to Provide Cloth Masks to Critical Infrastructure The Federal Emergency Management Agency (FEMA) has initiated... View Article
April 20, 2020
SOCMA has gathered information on high-demand products used to combat COVID-19 and partnered with EchoSystem to support B2B connection.
April 19, 2020
